Table of Contents

company-logo

Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The company's diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer's disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with multiple sclerosis. Its therapeutic products in development comprise Eltoprazine, a small molecule drug for the treatment of Parkinson's disease Levadopa-Induced Dyskinesia and attention deficit hyperactivity disorders; and mesencephalic-astrocyte-derived neurotrophic factor for the treatment of various animal models, including retinitis pigmentosa and retinal artery occlusion. It also develops NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinson's disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. In addition, the company develops Engineered Skin Substitute (ESS), a cell therapy-based autologous skin replacement product that is in mid-stage clinical development for the treatment of life-threatening severe burns. Amarantus BioScience Holdings, Inc. has a cooperative research and development agreement with the U.S. Army Institute of Surgical Research and Rutgers University. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus BioScience Holdings, Inc. in April 2013. Amarantus BioScience Holdings, Inc. was founded in 2008 and is headquartered in New York, New York.

Amarantus BioScience Dividend Announcement

• Amarantus BioScience does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Amarantus BioScience dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Amarantus BioScience Dividend History

Amarantus BioScience Dividend Yield

Amarantus BioScience current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Amarantus BioScience stock? Use our calculator to estimate your expected dividend yield:

Amarantus BioScience Financial Ratios

P/E ratio0.00
PEG ratio0.00
P/B ratio0.00
ROE0.00%
Payout ratio0.00%
Current ratio0.00
Quick ratio0.00
Cash Ratio0.00

Amarantus BioScience Dividend FAQ

Does Amarantus BioScience stock pay dividends?
Amarantus BioScience does not currently pay dividends to its shareholders.
Has Amarantus BioScience ever paid a dividend?
No, Amarantus BioScience has no a history of paying dividends to its shareholders. Amarantus BioScience is not known for its dividend payments.
Why doesn't Amarantus BioScience pay dividends?
There are several potential reasons why Amarantus BioScience would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Amarantus BioScience ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Amarantus BioScience has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Amarantus BioScience a dividend aristocrat?
Amarantus BioScience is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Amarantus BioScience a dividend king?
Amarantus BioScience is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Amarantus BioScience a dividend stock?
No, Amarantus BioScience is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Amarantus BioScience stocks?
To buy Amarantus BioScience you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Amarantus BioScience stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.